Analysts Anticipate Biodesix, Inc. (NASDAQ:BDSX) Will Post Earnings of -$0.38 Per Share

Analysts expect Biodesix, Inc. (NASDAQ:BDSXGet Rating) to post earnings of ($0.38) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Biodesix’s earnings. The highest EPS estimate is ($0.35) and the lowest is ($0.41). Biodesix posted earnings of ($0.23) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 65.2%. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Biodesix will report full-year earnings of ($1.13) per share for the current financial year, with EPS estimates ranging from ($1.37) to ($0.89). For the next fiscal year, analysts forecast that the business will post earnings of ($0.72) per share, with EPS estimates ranging from ($0.91) to ($0.53). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Biodesix.

Biodesix (NASDAQ:BDSXGet Rating) last announced its earnings results on Monday, March 14th. The company reported ($0.49) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.49). During the same period in the prior year, the firm earned ($0.25) earnings per share.

A number of equities research analysts have commented on BDSX shares. Canaccord Genuity Group decreased their price target on Biodesix from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, February 15th. Zacks Investment Research cut Biodesix from a “buy” rating to a “hold” rating in a report on Thursday, March 17th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $15.35.

Biodesix stock traded down $0.06 during trading on Wednesday, reaching $1.62. The company had a trading volume of 994 shares, compared to its average volume of 117,684. Biodesix has a 52 week low of $1.62 and a 52 week high of $19.76. The firm’s 50-day simple moving average is $2.53 and its 200 day simple moving average is $4.92. The firm has a market capitalization of $50.72 million, a price-to-earnings ratio of -1.03 and a beta of 2.27.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of Biodesix by 1.1% in the fourth quarter. BlackRock Inc. now owns 577,242 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,070 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Biodesix by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 160,940 shares of the company’s stock valued at $851,000 after buying an additional 9,917 shares during the period. Morgan Stanley boosted its position in shares of Biodesix by 148.9% during the third quarter. Morgan Stanley now owns 108,523 shares of the company’s stock valued at $892,000 after buying an additional 64,919 shares during the period. Citadel Advisors LLC boosted its position in shares of Biodesix by 20.1% during the second quarter. Citadel Advisors LLC now owns 54,118 shares of the company’s stock valued at $715,000 after buying an additional 9,069 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of Biodesix in the fourth quarter valued at approximately $275,000. 75.82% of the stock is currently owned by hedge funds and other institutional investors.

About Biodesix (Get Rating)

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

Featured Stories

Get a free copy of the Zacks research report on Biodesix (BDSX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Biodesix (NASDAQ:BDSX)

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with's FREE daily email newsletter.